Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

Phase 2 Recruiting 35 enrolled Peking Union Medical College Hospital

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II study in patients with newly diagnosed Mayo stage IIIB immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab

Timeline

Start: 2025-06-28
Primary completion: 2027-01-31
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Teclistamab	Monoclonal antibody	—	Subcutaneous

Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

Summary

Timeline

Drugs

Indications